Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Australian Clinical Labs Ltd ( (AU:ACL) ) just unveiled an update.
Australian Clinical Labs Ltd has announced an update regarding its ongoing on-market buy-back program. As of November 14, 2025, the company has repurchased a total of 399,627 ordinary fully paid securities, with 200,000 bought back on the previous day. This buy-back initiative is part of the company’s strategy to optimize its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Ltd operates in the healthcare industry, primarily focusing on providing pathology services. The company is known for its comprehensive range of diagnostic testing services, catering to various healthcare needs across Australia.
Average Trading Volume: 990,363
Technical Sentiment Signal: Sell
Current Market Cap: A$528.6M
For detailed information about ACL stock, go to TipRanks’ Stock Analysis page.